跳至主要内容
临床试验/NL-OMON37315
NL-OMON37315已完成不适用

Reflux symptoms in patients with achalasia. - Reflux symptoms in achalasia

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Treated achalasia patients WITH gastroesophageal reflux symptoms
  • 1) Diagnosis of idiopathic achalasia confirmed by esophageal manometry that shows the following criteria:
  • - Aperistalsis or simultaneous contractions in the esophageal body.
  • - LES dysrelaxation.
  • 2) Treatment of achalasia with one of the following procedures:
  • - Endoscopic balloon dilatation
  • - Surgical Heller myotomy
  • - Per-oral endoscopic myotomy (POEM)
  • 3) Minimum total score on the GastroEsophageal Reflux Disease Questionnaire (GERDQ) of * 8.
  • 4) Gastroesophageal symptoms after treatment lasting more than 3 months.
  • 5) Age 18-80 years.
  • 6) Written informed consent.;Treated achalasia patients WITHOUT gastroesophageal reflux symptoms
  • 1) Diagnosis of idiopathic achalasia confirmed by esophageal manometry that shows the following criteria:
  • - Aperistalsis or simultaneous contractions in the esophageal body.
  • - LES dysrelaxation.
  • 2) Treatment of achalasia with one of the following procedures:
  • - Endoscopic balloon dilatation
  • - Surgical Heller myotomy
  • - Per-oral endoscopic myotomy (POEM)
  • 3) Maximum total score on the GastroEsophageal Reflux Disease Questionnaire (GERDQ) of < 8.
  • 4) No gastroesophageal symptoms after treatment.
  • 5) Age 18-80 years.
  • 6) Written informed consent.

排除标准

  • Treated achalasia patients WITH gastroesophageal reflux symptoms
  • - Pseudoachalasia.
  • - Upper gastrointestinal malignancy.
  • - Chagas disease.
  • - Peptic ulcer disease.
  • - Inability to stop PPI, H2-receptor antagonist or prokinetic drug for two weeks.
  • - Presence of an extremely dilated oesophagus body >5 cm.;Treated achalasia patients WITHOUT gastroesophageal reflux symptoms
  • - Pseudoachalasia.
  • - Upper gastrointestinal malignancy.
  • - Chagas disease.
  • - Peptic ulcer disease.
  • - Inability to stop PPI, H2-receptor antagonist or prokinetic drug for two weeks.
  • - Presence of an extremely dilated oesophagus body >5 cm.

研究者

相似试验